Opendata, web and dolomites

InDx SIGNED

InDx - an innovative implant that restores natural motion to patients with thumb base joint arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InDx project word cloud

Explore the words cloud of the InDx project. It provides you a very rough idea of what is the project "InDx" about.

functional    fundamental    ireland    europeans    ftes    ce    base    accommodate    station    endolab    natural    usa    university    lags    estimates    irish    sme    jar    healthcare    surgical    24    trl    movement    implant    humanitarian    anatomy    dexterity    first    launch    orthopaedics    prepare    innovation    validate    burden    impossible    marking    implants    opening       commercialisation    human    disruptive    approximately    organization    dressed    substantial    start    25    spin    suffers    fda    company    prone    loci    namsa    socioeconomic    door    joint    international    market    designed    medvie    stage    world    dynamic    months    51m    510k    led    employment    stages    running    uk    clinical    expertise    causes    date    indx    investigations    population    joints    extensive    thumb    galway    biomechanics    small    arthritis    million    germany    treatment    commercialization    restore    debilitating    cumulative    medical    national    revenues    approval    final   

Project "InDx" data sheet

The following table provides information about the project.

Coordinator
LOCI ORTHOPAEDICS LIMITED 

Organization address
address: UNIT 209 NUIG BUSINESS INNOVATION CENTRE UPPER NEWCASTLE
city: GALWAY
postcode: H91 V207
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙633˙125 €
 EC max contribution 2˙543˙187 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOCI ORTHOPAEDICS LIMITED IE (GALWAY) coordinator 1˙746˙500.00
2    NORTH AMERICAN SCIENCE ASSOCIATES LIMITED UK (SELBY) participant 319˙812.00
3    Medvie Limited IE (MALAHIDE) participant 280˙000.00
4    ENDOLAB MECHANICAL ENGINEERING GMBH DE (RIEDERING) participant 196˙875.00

Map

 Project objective

The thumb base joint is fundamental for human dexterity and functional activity but is prone to debilitating arthritis. Approximately 5% of the world population suffers from this condition with over 25 million Europeans affected. Simple tasks become impossible such as getting dressed, opening a jar, using a key to open a door. This is certainly a relevant socioeconomic and humanitarian concern, which causes a substantial cost burden on healthcare systems, yet the effective treatment for end-stage thumb base arthritis lags far behind other joints, given challenges of the small, complex anatomy. The InDx project aims to enable the commercialization of the InDx implant, the world’s first implant designed to accommodate the complex biomechanics of the thumb base joint and restore the natural movement of the thumb. The consortium is led by Loci Orthopaedics, a technology-driven SME spin-out company from the National University of Ireland, Galway. The partners include EndoLab in Germany, that has developed a novel dynamic test station for implants, NAMSA in the UK, a leading medical research organization with extensive experience in running international clinical investigations, and Medvie, an Irish based SME with extensive project management, dissemination and commercialization expertise. Together, the consortium have brought the implant to TRL 6 level. As part of the InDx project, the consortium will undertake the final stages of product development and will validate clinical results in a clinical study that will prepare the CE marking and market access. Market launch is planned within 24 months from the project start date, following FDA 510K approval in the USA and CE marking in Europe. The consortium estimates cumulative revenues of €51M within 5 years from the start of commercialisation and an employment growth of 25 FTEs for the consortium partners. The InDx has the potential to be a disruptive innovation in the surgical management of thumb base joint arthritis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INDX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INDX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

PAV-DT (2019)

A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.

Read More  

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

HYDRACTFLEX (2019)

Full-scale demonstration of a flexible inline production concept for breweries, drawing on water hydraulics

Read More